Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 3, 2012, Pages 308-317

  Elstrand, Mari B ^a   Sandstad, Berit ^b   Oksefjell, Halldis ^c   Davidson, Ben ^d   Tropé, Claes G ^c,d  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b Unit for Biostatistics and Epidemiology   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; FIGO stage IV; ovarian carcinoma; residual tumor; surgery; survival

Indexed keywords

PACLITAXEL; PLATINUM DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALGORITHM; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84857539849     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2011.01316.x     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available online at:. (Last accessed 10 May 2011).
2. Goodman MT, Correa CN, Tung KH, Roffers SD, Cheng Wu X, Young JL Jr, et al,. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer. 2003; 97: 2648-59. (Pubitemid 36539066)
3. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al,. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;(Suppl 1): S161-92.
4. Griffiths CT,. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975; 42: 101-4.
5. Munkarah AR, Hallum AV, Morris M, Burke TW, Levenback C, Atkinson EN, et al,. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997; 64: 13-17. (Pubitemid 27026950)
6. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ,. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997; 64: 9-12. (Pubitemid 27026949)
7. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC,. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 1997; 64: 4-8. (Pubitemid 27026948)
8. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al,. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001; 81: 398-403. (Pubitemid 32494653)
9. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY,. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999; 72: 278-87. (Pubitemid 29118182)
10. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ,. Suvival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20: 1248-59. (Pubitemid 34177431)
11. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al,. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2008; 26: 83-9.
12. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, et al,. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. Ann Surg Oncol. 2010; 17: 1642-8.
13. Aletti GD, Dowdy SC, Podratz KC, Cliby WA,. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007; 105: 84-9. (Pubitemid 46441445)
14. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS,. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008; 108: 276-81.
15. Kang S, Nam BH,. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009; 16: 2315-20.
16. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al,. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-53.
17. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al,. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995; 332: 629-34.
18. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al,. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004; 24: 2489-97.
19. Bristow RE, Eisenhauer EL, Santillan A, Chi DS,. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007; 104: 480-90. (Pubitemid 46135675)
20. Ozols RF,. Treatment goals in ovarian cancer. Int J Gynecol Cancer. 2005; 15 (Suppl 1): 3-11. (Pubitemid 40696471)
21. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P,. Neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998; 71: 431-6. (Pubitemid 29022333)
22. Bristow RE, Chi DS,. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006; 103: 1070-6. (Pubitemid 44821335)
23. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, et al,. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007; 105: 211-7. (Pubitemid 46441463)
24. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al,. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996; 60: 412-7. (Pubitemid 26077628)
25. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R,. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2003; 13: 120-4. (Pubitemid 37055464)
26. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA,. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer. 2004; 101: 346-52. (Pubitemid 38890839)
27. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, et al,. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol. 2004; 190: 910-25. (Pubitemid 38561506)
28. Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, et al,. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Cancer. 2006; 100: 455-61. (Pubitemid 43246859)
29. Rafii A, Deval B, Geay JF, Chopin N, Paoletti X, Paraiso D, et al,. Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective tudy. Int J Gynecol Cancer. 2007; 27: 777-83. (Pubitemid 47063342)